πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 64 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9969998

Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same

HALOZYME, INC. Β· Granted Tue May 15 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 10 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9963450

A3 adenosine receptor agonists

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue May 08 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9549943

A3 adenosine receptor ligands for use in treatment of a sexual dysfunction

CAN-FITE BIOPHARMA LTD. Β· Granted Tue Jan 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9415105

Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Aug 16 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9326978

A3 adenosine receptor allosteric modulators

THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT. HEALTH & HUMAN SERVICES Β· Granted Tue May 03 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9181253

Adenosine receptor agonists, partial agonists, and antagonists

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Nov 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9018371

Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositio

THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFERβ€”NATIONAL INSTITUTES OF HEALTH Β· Granted Tue Apr 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8987228

Pharmaceutical composition including an A3 adenosine receptor agonist 1-deooxy-1-[N6-(3-id

CAN-FITE BIOPHARMA LTD. Β· Granted Tue Mar 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8916570

A3 adenosine receptor agonists and antagonists

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Dec 23 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8883500

Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherap

Northwestern University Β· Granted Tue Nov 11 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8796291

A3 adenosine receptor antagonists and partial agonists

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Aug 05 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 31 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8735407

Purine derivatives as A3 adenosine receptor-selective agonists

The United States of America as Represented by the Secretary of the Department of Health and Human Services Β· Granted Tue May 27 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 22 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8716301

Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue May 06 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 01 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8518957

Methanocarba adenosine derivatives, pharmaceutical compositions, and method of reducing in

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Aug 27 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8513214

C4β€²-substituted-2-deoxyadenosine analogs and methods of treating HIV

The United States of America as represented by the Secretary of the Dept. of Health & Human Services Β· Granted Tue Aug 20 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 15 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8420664

A3 adenosine receptor allosteric modulators

THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT. HEALTH & HUMAN SERVICES Β· Granted Tue Apr 16 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8349848

Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors

Dogwood Pharmaceuticals, Inc. Β· Granted Tue Jan 08 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 03 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8263762

Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as A2AR agonists

Dogwood Pharmaceuticals, Inc. Β· Granted Tue Sep 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8080554

Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to

The United States of America as Represented by the Secretary of the Department of Health and Human Services Β· Granted Tue Dec 20 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7855202

Imidazopyridine derivatives as A2B adenosine receptor antagonists

Laboratories Almirall, S.A. Β· Granted Tue Dec 21 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 16 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7825126

Purine derivatives as A3 and A1 adenosine receptor agonists

The United States of America, as represented by the Department of Health and Human Services Β· Granted Tue Nov 02 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 28 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7790728

Pyrazine derivatives useful as adenosine receptor antagonists

Laboratories Almirall, S.A. Β· Granted Tue Sep 07 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 02 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7767686

Method of using adenosine receptor blockers during tissue ablation

Covidien LP Β· Granted Tue Aug 03 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 29 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7589075

Use of an adenosine A3 receptor agonist for inhibition of viral replication

CAN-FITE BIOPHARMA LTD. Β· Granted Tue Sep 15 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 10 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted